NewAmsterdam Pharma BV

Many public biopharmaceutical companies have taken advantage of the ongoing capital markets recovery in 2024 by raising money through follow-on public offerings (FOPOs) after announcing key research a

Cytokinetics Brought Down In the earlier halcyon days of biotech, the licensing of a biotech company’s lead drug to a big pharma partner would be associated with a substantial jump in the licensor’s

NewAmsterdam Pharma Company has added more evidence that its CETP inhibitor obicetrapib is effective at lowering low-density lipoprotein cholesterol (LDL-C) in patients at risk of cardiovascular disea

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip 's global team, in this podcast version of Five Must-Know Things. This ep